Cargando…

Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility

The integrase strand transfer inhibitor (INSTI)-resistance mutations Q148H/K/R are arguably the most important INSTI-resistance mutations as they represented the first step to high-level dolutegravir cross-resistance. We describe an individual with transmitted four-class drug resistance whose virus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varghese, Vici, Pinsky, Benjamin A., Smith, Darvin S., Klein, Daniel, Shafer, Robert W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2016
Materias:	Sequence Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931751/ https://www.ncbi.nlm.nih.gov/pubmed/27009474 http://dx.doi.org/10.1089/aid.2016.0038

Ejemplares similares

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
por: Blanco, Jose-Luis, et al.
Publicado: (2011)

HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J recombination
por: Nishana, Mayilaadumveettil, et al.
Publicado: (2017)

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method
por: Midde, Narasimha M., et al.
Publicado: (2016)

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
por: Delelis, Olivier, et al.
Publicado: (2009)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
por: Ni, Xiao-Ju, et al.
Publicado: (2011)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations
por: Charpentier, Charlotte, et al.
Publicado: (2018)

1568 Use of the Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in a Predominantly African-American HIV Infected Population
por: Bryant, Paul, et al.
Publicado: (2014)

Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors
por: Kayondo, Jonathan K., et al.
Publicado: (2015)

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa
por: Sutherland, Katherine A., et al.
Publicado: (2015)

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations
por: Nguyen, Nga, et al.
Publicado: (2013)

Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors
por: Weber, Jan, et al.
Publicado: (2013)

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
por: Babrzadeh, Farbod, et al.
Publicado: (2013)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
por: Pandey, Krishan K
Publicado: (2014)

Clinical features and disease severity of Turkish FMF children carrying E148Q mutation
por: Aydın, Fatma, et al.
Publicado: (2019)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment
por: El Bouzidi, Kate, et al.
Publicado: (2020)

ARCHITECT HIV Combo Ag/Ab and RealTime HIV-1 Assays Detect Diverse HIV Strains in Clinical Specimens
por: Rodgers, Mary A., et al.
Publicado: (2018)

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
por: Perez-Valero, Ignacio, et al.
Publicado: (2021)

Amyloid goiter secondary to familial Mediterranean fever with E148Q mutation: A unique case
por: Moreno, Juan C. A., et al.
Publicado: (2023)

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
por: Abram, Michael E., et al.
Publicado: (2017)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Comparative Analysis of the Chloroplast Genomes of Quercus × morehus and the Presumptive Parents Q. wislizeni and Q. kelloggii (Fagaceae) from California
por: Garcia, Alejandro, et al.
Publicado: (2022)

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings
por: Lee, Janice Soo Fern, et al.
Publicado: (2012)

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response
por: Godse, Sandip, et al.
Publicado: (2023)

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response
por: Godse, Sandip, et al.
Publicado: (2023)

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
por: Siedner, Mark J., et al.
Publicado: (2020)

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
por: Rhee, Soo-Yon, et al.
Publicado: (2008)

G140S mutation rescues HIV-1 IN integration defect due to Q148H in vitro and in vivo
por: Delelis, Olivier, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v6esv7rjcukl3qk8309hpraobv